At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 385 enrolled
Drug / intervention
Zanubrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
In Brief
A Phase 2 clinical trial evaluating Zanubrutinib for B-cell Malignancies. Completed, enrolled 385 participants across 23 sites in 6 countries.
Detailed Summary
This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Malignancies
CountriesAustralia, Italy, New Zealand, South Korea, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedJan 2015
Primary CompletionMar 2021
TodayJul 2026
First PostedJan 21, 2015
Enrollment StartSep 4, 2014
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 11.4 years ago
Interventions
Zanubrutinibdrug
Oral administration by capsule